查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1751261

亨廷頓氏舞蹈症治療市場規模、佔有率、趨勢分析報告：按治療、分銷管道、地區和細分市場預測，2025 年至 2030 年

Huntington's Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Symptomatic Treatment, Disease-Modifying Therapies), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

亨廷頓氏舞蹈症治療市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，全球亨廷頓氏舞蹈症治療市場規模預計到2030年將達到18.712億美元，2025年至2030年的複合年成長率為23.8%。

這一成長得益於對新產品研發的高投入、合作研究以及西方國家亨廷頓舞蹈症的高負擔。亨廷頓舞蹈症是一種罕見的遺傳性神經退化性疾病，影響幾代。此病在30至50歲之間發病，會損害患者工作和照顧家庭的能力，最終導致患者無法進行日常活動。

不同地理位置的盛行率差異超過10倍，可能與病例確認和診斷標準的差異有關。不同地理位置的盛行率差異超過10倍，可能與病例確認和診斷標準的差異有關。因此，一般人群中復發性肥大的盛行率可能高於預期。亞洲的盛行率一直較低，而北美和澳洲的盛行率較高。

Neurocrine Biosciences 和 Azevan Pharmaceuticals 等大型公司專注於亨廷頓舞蹈症（HD）症狀治療的研發。 Azevan Pharmaceuticals 正在開發 SRX246，作為一種實驗性藥物，用於治療亨廷頓舞蹈症的神經精神症狀。 SRX246 透過阻斷大腦中的加壓素 1a (V1a) 受體來發揮作用。在神經系統中，V1a 受體是主要的加壓素受體。透過阻斷 V1a 受體，SRX246 可以限制加壓素與此受體結合，從而避免亨廷頓舞蹈症患者出現易怒和攻擊性行為。

然而，目前核准的藥物僅限於症狀治療或安寧療護，而非針對疾病的根本病因。藥物治療雖然可以嚴重症狀，但常伴隨嗜睡、步態障礙、吞嚥障礙和嗜睡等副作用，嚴重影響患者的生活品質。鑑於該疾病尚無明確的治療方法，評估這些患者的健康相關生活品質 (HRQOL) 受到的影響至關重要。處於疾病早期至中期的亨廷頓氏症 (HD) 患者需要多學科醫療服務，包括認知評估和諮詢。

亨廷頓舞蹈症（HD）的藥物開發面臨巨大障礙，一些治療方法未能證明療效或伴隨顯著毒性。 2020年9月，Vaccinex Inc. 的 pepinemab 的一項 II 期研究未能達到早期症狀型和前驅型亨廷頓舞蹈症患者的預設共同主要終點。在 SIGNAL 研究中，兩個共同主要終點（兩個認知結局，即亨廷頓舞蹈症認知評估系統和臨床總體印象變化 (CGIC)）在早期症狀人群中未達到統計學意義。

亨廷頓氏舞蹈症治療市場報告重點

  • 由於產品供應充足且專利保護到位，預計對症治療領域將在2024年佔據最大收入佔有率。由於SAGE-718和Cellavita-HD的進入，疾病修正治療預計將成為預測期內成長最快的領域。
  • 目前，各公司並不專注於針對突變蛋白，而是專注於開發可直接注射到大腦中以直接阻止突變 HTT 蛋白形成的治療方法。
  • 處於早期開發階段的具有新標靶的藥物包括 Cellavita 和 Azidus Brazil 的 Cellavita HD（幹細胞療法）、Sangamo Therapeutics 的 mHTT ZFP（鋅指蛋白）和 UniQure 的 AMT-130（基因療法）。
  • 預計北美將在 2024 年佔據最高的收益佔有率，而由於該地區擁有龐大的報銷機構和較高的 HD 負擔，預計美國和加拿大將在預測期內主導市場。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章市場變數、趨勢和範圍

  • 市場展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 亨丁頓舞蹈症治療市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 定價分析
    • 管道分析

第4章 亨廷頓舞蹈症治療市場：治療評估與趨勢分析

  • 全球亨廷頓舞蹈症治療市場：治療儀表板
  • 全球亨廷頓氏舞蹈症治療市場：治療變異分析
  • 亨丁頓舞蹈症治療市場（依治療方法、收益）
  • 治療
  • 疾病修正治療

第5章亨廷頓氏舞蹈症治療市場：通路評估與趨勢分析

  • 全球亨廷頓舞蹈症治療市場：分銷通路儀表板
  • 全球亨廷頓舞蹈症治療市場：通路變化分析
  • 亨廷頓氏舞蹈症治療市場（按分銷管道和收益）
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第6章 亨廷頓舞蹈症治療市場：按治療、應用和分銷管道分類的區域估計和趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模、預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要經銷商和通路合作夥伴名單
    • Key customers
    • 2024 年主要公司市佔率分析
    • H. Lundbeck A/S.
    • Teva Pharmaceutical Industries Ltd.
    • Bausch Health Companies Inc.
    • Hetero
    • Lupin
    • Hikma Pharmaceuticals PLC
    • Dr. Reddy's Laboratories Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Novartis AG
    • uniQure NV.
    • Latus Bio
Product Code: GVR-2-68038-552-6

Huntington's Disease Treatment Market Growth & Trends:

The global huntington's disease treatment market size is expected to reach USD 1,871.2 million by 2030, registering a CAGR of 23.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth is due to high R&D investments for new product development, research collaboration, and the high HD burden in western countries. Huntington's disease is a rare inherited neurodegenerative disease that affects several generations. It affects people between the ages of 30 and 50, impairing their capacity to work, care for their families, and, eventually, complete daily tasks.

The prevalence varies by more than ten-fold between geographical locations, which can be related to variations in case ascertainment and diagnostic criteria. The prevalence varies by more than ten-fold between geographical locations, which can be related to variations in case ascertainment and diagnostic criteria. As a result, the prevalence of enlarged repetitions in the general population may be greater than expected. The Asian population has consistently had a lower prevalence, while Europe, North America, and Australia have a higher prevalence.

The key players, such as Neurocrine Biosciences, Inc. and Azevan Pharmaceuticals, Inc., are focusing on research and development of symptomatic therapies for HD. Azevan Pharmaceuticals is developing SRX246 as an experimental drug to treat neuropsychiatric symptoms in Huntington's disease. SRX246 is a drug that works by blocking the vasopressin 1a (V1a) receptor in the brain. In the neurological system, V1a receptor is the major vasopressin receptor. SRX246 works by inhibiting the V1a receptor, restricting vasopressin from attaching to the receptor, and generating irritable and aggressive behavior, which is seen in Huntington's disease patients.

However, currently approved drugs provide symptomatic and palliative care and do not target the underlying cause of the disease. While medications can decrease the severity of symptoms, they are often associated with adverse effects such as somnolence, gait issues, dysphagia, and apathy, which can have serious impacts on a patient's quality of life. Given the lack of a cure for the disease, it is critical to evaluate how Health-related Quality of Life (HRQOL) is affected in these patients. HD patients in early to middle stages of the disease need coordinated multidisciplinary healthcare services, including assessment of cognitive function and counseling.

Drug development for HD has faced significant obstacles as several therapies have failed to demonstrate efficacy or were associated with significant toxicity. Vaccinex Inc.'s phase II trial of Pepinemab failed to satisfy pre-specified co-primary endpoints in patients with early manifest and prodromal HD, in September 2020. The two co-primary endpoints-a family of two cognitive evaluations from the Huntington's disease Cognitive Assessment Battery and Clinical Global Impression of Change (CGIC)-did not attain statistical significance in the early manifestation population in the SIGNAL study.

Huntington's Disease Treatment Market Report Highlights:

  • The symptomatic treatment segment accounted for the largest revenue share in 2024 owing to the product availability and patent protection. Disease-modifying therapies is anticipated to be the fastest-growing segment over the forecast years due to the entry of SAGE-718, and Cellavita-HD
  • Companies are now focusing on the development of treatments that can be injected directly into the brain to directly inhibit the formation of mutant HTT protein, instead of targeting the mutant protein
  • Drugs with novel targets in early-phase development include Cellavita and Azidus Brazil's Cellavita HD (stem cell therapy), Sangamo Therapeutics, Inc. mHTT ZFP (zinc finger protein), and UniQure's AMT-130 (gene therapy)
  • North America held the highest revenue share in 2024 and is expected to dominate the market over the forecast period due to better reimbursement facilities and the high burden of HD in the U.S. and Canada

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. Distribution Channel
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment and Distribution Channel Outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising anti-aging burden
      • 3.2.1.2. Advancements in drug development
      • 3.2.1.3. Growing awareness about anti-aging treatment
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of development
      • 3.2.2.2. Regulatory challenges for new drug approvals
  • 3.3. Huntington's Disease Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis
    • 3.3.4. Pipeline Analysis
      • 3.3.4.1. Phase 1
      • 3.3.4.2. Phase 2
      • 3.3.4.3. Phase 2

Chapter 4. Huntington's Disease Treatment Market: Treatment Estimates & Trend Analysis

  • 4.1. Global Huntington's Disease Treatment Market: Treatment Dashboard
  • 4.2. Global Huntington's Disease Treatment Market: Treatment Movement Analysis
  • 4.3. Global Huntington's Disease Treatment Market by Treatment, Revenue
  • 4.4. Symptomatic Treatment
    • 4.4.1. Symptomatic Treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5. Disease-modifying Therapies
    • 4.5.1. Disease-modifying Therapies market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Huntington's Disease Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 5.1. Global Huntington's Disease Treatment Market: Distribution Channel Dashboard
  • 5.2. Global Huntington's Disease Treatment Market: Distribution Channel Movement Analysis
  • 5.3. Global Huntington's Disease Treatment Market by Distribution Channel, Revenue
  • 5.4. Hospital Pharmacy
    • 5.4.1. Hospital Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5. Retail Pharmacy
    • 5.5.1. Retail Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6. Online Pharmacy
    • 5.6.1. Online Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Huntington's Disease Treatment Market: Regional Estimates & Trend Analysis by Treatment, Application, and Distribution Channel

  • 6.1. Regional Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2024
    • 7.3.4. H. Lundbeck A/S.
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Teva Pharmaceutical Industries Ltd.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Treatment benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Bausch Health Companies Inc.
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Hetero
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Lupin
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Hikma Pharmaceuticals PLC
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Dr. Reddy's Laboratories Ltd.
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Sun Pharmaceutical Industries Ltd.
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Novartis AG
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. uniQure NV.
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives
    • 7.3.14. Latus Bio
      • 7.3.14.1. Company overview
      • 7.3.14.2. Financial performance
      • 7.3.14.3. Product benchmarking
      • 7.3.14.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 3 North America Huntington's Disease Treatment Market, by Distribution Channel 2018 - 2030 (USD Million)
  • Table 4 U.S. Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 5 U.S. Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 6 Canada Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 7 Canada Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 8 Mexico Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 9 Mexico Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 Europe Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 11 Europe Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 12 Germany Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 13 Germany Huntington's Disease Treatment Market, by Application, 2018 - 2030 (USD Million)
  • Table 14 UK Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 15 UK Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 France Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 17 France Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 18 Italy Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 19 Italy Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 Spain Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 21 Spain Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 22 Asia Pacific Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 23 Asia Pacific Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24 China Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 25 China Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 Japan Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 27 Japan Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 28 India Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 29 India Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30 South Korea Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 31 South Korea Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Latin America Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 33 Latin America Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 34 Brazil Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 35 Brazil Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 MEA Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 37 MEA Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 South Africa Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 39 South Africa Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 Saudi Arabia Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 41 Saudi Arabia Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 42 UAE Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 43 UAE Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Kuwait Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 45 Kuwait Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Huntington's Disease Treatment Market Segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Treatment and Distribution Channel segment snapshot
  • Fig. 10 Distribution Channel segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Pharmaceutical market (USD Billion)
  • Fig. 13 Market dynamics
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 PESTLE analysis
  • Fig. 16 Huntington's Disease Treatment market: Treatment outlook and key takeaways
  • Fig. 17 Huntington's Disease Treatment market: Treatment movement analysis
  • Fig. 18 Symptomatic Treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Disease-modifying Therapies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Huntington's Disease Treatment market: Distribution Channel outlook and key takeaways
  • Fig. 21 Huntington's Disease Treatment Market: Distribution Channel movement analysis
  • Fig. 22 Hospital Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Retail Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Online Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Huntington's Disease Treatment market revenue, by region, 2024 & 2030, (USD million)
  • Fig. 26 Regional marketplace: Key takeaways
  • Fig. 27 Regional marketplace: Key takeaways
  • Fig. 28 North America Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Key country dynamics
  • Fig. 30 Target disease prevalence
  • Fig. 31 U.S. Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Key country dynamics
  • Fig. 33 Target disease prevalence
  • Fig. 34 Canada Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Mexico Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Key country dynamics
  • Fig. 37 Target disease prevalence
  • Fig. 38 Europe Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Key country dynamics
  • Fig. 40 Target disease prevalence
  • Fig. 41 UK Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 Target disease prevalence
  • Fig. 44 Germany Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Key country dynamics
  • Fig. 46 Target disease prevalence
  • Fig. 47 France Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Target disease prevalence
  • Fig. 50 Spain Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 Target disease prevalence
  • Fig. 53 Italy Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 Target disease prevalence
  • Fig. 56 Denmark Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Target disease prevalence
  • Fig. 59 Sweden Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Target disease prevalence
  • Fig. 62 Norway Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Asia Pacific Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Target disease prevalence
  • Fig. 66 Japan Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Target disease prevalence
  • Fig. 69 China Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Target disease prevalence
  • Fig. 72 India Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Target disease prevalence
  • Fig. 75 Australia Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Thailand Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 South Korea Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Latin America Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Key country dynamics
  • Fig. 82 Target disease prevalence
  • Fig. 83 Brazil Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Target disease prevalence
  • Fig. 86 Argentina Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 MEA Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 Target disease prevalence
  • Fig. 90 South Africa Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Key country dynamics
  • Fig. 92 Target disease prevalence
  • Fig. 93 Saudi Arabia Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Key country dynamics
  • Fig. 95 Target disease prevalence
  • Fig. 96 UAE Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Key country dynamics
  • Fig. 98 Target disease prevalence
  • Fig. 99 Kuwait Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)